CLS B — Clinical Laserthermia Systems AB Income Statement
0.000.00%
Last trade - 00:00
- SEK108.71m
- SEK91.60m
- SEK8.27m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | SAS | SAS | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.43 | 1.33 | 2.25 | 6.27 | 8.27 |
Cost of Revenue | |||||
Gross Profit | -37.4 | -39.3 | -46.3 | -49.1 | -39.8 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 43.8 | 53.4 | 62.9 | 73.7 | 74.2 |
Operating Profit | -42.4 | -52.1 | -60.7 | -67.4 | -65.9 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -43.4 | -57.9 | -64.1 | -71.3 | -80.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -43.4 | -57.9 | -64.1 | -71.3 | -80.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -43.4 | -57.9 | -63.6 | -70.7 | -79.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -43.4 | -57.9 | -63.6 | -70.7 | -79.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -61.6 | -66.6 | -58.1 | -55 | -23.8 |
Dividends per Share |